Veerakiet Boonkanokwong

Dr. Veerakiet Boonkanokwong

Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Krung Thep Maha Nakhon, Thailand
orcid
Associate Professor

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Powder Technology
Verified
Journal Article
Closed access
Veerakiet BoonkanokwongVeerakiet Boonkanokwong
Veerakiet Boonkanokwong
BRBrenda Remy
Brenda Remy
Johannes KhinastJohannes Khinast
Johannes Khinast
BGBenjamin J. Glasser
Benjamin J. Glasser

20 October 2023 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MGMaxius Gunawan
Maxius Gunawan
Veerakiet BoonkanokwongVeerakiet Boonkanokwong
Veerakiet Boonkanokwong

1 November 2018 in Advanced Powder Technology
Verified
Journal Article
Closed access
Veerakiet BoonkanokwongVeerakiet Boonkanokwong
Veerakiet Boonkanokwong
RFRohan P. Frank
Rohan P. Frank
PVPavithra Valliappan
Pavithra Valliappan
BRBrenda Remy
Brenda Remy
Johannes KhinastJohannes Khinast
Johannes Khinast
BGBenjamin J. Glasser
Benjamin J. Glasser

15 October 2024 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
TRTissana Rojanaratha
Tissana Rojanaratha
PTPaisan Tienthai
Paisan Tienthai
WWWarunya Woradulayapinij
Warunya Woradulayapinij
TYThunyatorn Yimsoo
Thunyatorn Yimsoo
Veerakiet BoonkanokwongVeerakiet Boonkanokwong
Veerakiet Boonkanokwong
GRGarnpimol C. Ritthidej
Garnpimol C. Ritthidej
Asiatic acid (AA) has neuroprotective potential for prevention and treatment of Alzheimer's disease. Natural waxes with various ratios of Tween 80 and Span 80 or soybean lecithin were formulated to obtain AA-loaded solid lipid nanoparticles (AA-SLN) to improve direct nose to brain transport. Optimal AA-SLN had particle size below 200 nm with uniform size distribution and zeta potential of nearly -30 mV indicating a low risk of particle aggregation. Formulation with rice bran wax, Tween 80, and soybean lecithin (AA-RwS100) showed the highest entrapment efficiency and yield of >98 % while in vitro AA release of AA-SLN was linearly up to 48 h For ex vivo permeation, confocal laser scanning microscopy (CLSM) and histopathological studies on porcine olfactory mucosa (OM) and respiratory mucosa (RM), AA-SLN showed significantly higher permeation across OM than RM (p < 0.05) up to 6 h and AA-RwS100 also showed the highest amount of drug permeated as confirmed by CLSM results. Although AA-SLN showed non-significantly lower permeation than AA solution (AA-SOL) (p > 0.05), no epithelial and mucosal structure damages were observed in OM treated with AA-RwS100 and RM treated with all AA-SLNs indicating safety for nasal administration while AA-SOL showed significant damage to both OM and RM. In addition, in vivo brain distribution study by fluorescence imaging using Rhodamine (R6g) showed higher brain distribution after intranasal administration of R6g-loaded solid lipid nanoparticles (R6g-SLN) than R6g solution (R6g-SOL) and intravenous administration of R6g-SLN, and R6g-RwS100 also showed the highest brain accumulation at 8 h post administration.

17 July 2022 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
WAWai Thet Aung
Wai Thet Aung
HKHnin Ei Ei Khine
Hnin Ei Ei Khine
CCChatchai Chaotham
Chatchai Chaotham
Veerakiet BoonkanokwongVeerakiet Boonkanokwong
Veerakiet Boonkanokwong
The purpose of this study was to develop astaxanthin (AST)-loaded self-microemulsifying drug delivery system (SMEDDS) tablets and evaluate their physicochemical and biological properties. The optimized liquid (L)-AST SMEDDS formulation was composed of rice bran oil (33.67%), Kolliphor® RH 40 (34.70%), and Span® 20 (31.63%). Two types of hydrophilic polymers (hydroxypropyl methylcellulose, HPMC, and polyvinyl alcohol, PVA) solutions were selected as a precipitation inhibitor for AST and incorporated into L-AST SMEDDS to obtain supersaturation and enhance dissolution of AST. The formulation was then mixed with microcrystalline cellulose and subsequently transformed to solid S-AST SMEDDS particles using a spray dryer prior to direct compression into tablets. The HPMC AST SMEDDS tablet and PVA AST SMEDDS tablet were characterized for their physicochemical properties, dissolution, AST release, and stabilities. Moreover, the cellular uptake and antioxidant effect of AST SMEDDS tablets were evaluated in Caco-2 cells. With good tablet characters, both HPMC AST SMEDDS tablet and PVA AST SMEDDS tablet dissolution profiles were improved compared to that of raw AST. While initially less than 50% of AST released from HPMC AST SMEDDS tablet and PVA AST SMEDDS tablet in pH 1.2 medium, after 6 h more than 98% of AST releases in pH 6.8 were achieved which was similar to L-AST SMEDDS profile. Cellular antioxidant activities of L-AST SMEDDS and HPMC AST SMEDDS tablet & PVA AST SMEDDS tablet were significantly greater than pure AST powder. HPMC AST SMEDDS tablet showed better uptake and deeper penetration through Caco-2 cells than that in PVA AST SMEDDS tablet and pure powder. Our successfully developed AST SMEDDS tablets were demonstrated to be a potential platform to deliver highly lipophilic AST and improve permeation and bioavailability.

1 January 2021 in The Thai Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MZMo Mo Ko Zin
Mo Mo Ko Zin
Veerakiet BoonkanokwongVeerakiet Boonkanokwong
Veerakiet Boonkanokwong
A self-microemulsifying delivery system (SMEDS) containing astaxanthin (AST) was developed and optimized using a mixture design and its desirability function. Independent factors studied in the experimental design were the amounts of castor oil, Cremophor® RH 40, and Tween® 80 in a formula. The measured response variables included droplet size, polydispersity index (PDI), zeta potential, active ingredient content, and transmittance of microemulsions obtained from the AST SMEDS formulations. The desirability function was then adjusted to optimize the formulation. The optimized AST SMEDS was composted of 19.59% castor oil, 62.34% Cremophor® RH 40, and 18.03% Tween® 80, and the resulting self microemulsions had an average droplet size of 22.55 nm with PDI of 0.27, zeta potential of –9.35 mV, 96.49% of AST content, and 98.80% of transmittance. Our results also showed the optimized formula could rapidly formed (self-emulsification time ~44 s) AST microemulsions with good physicochemical properties and stability conducted by the freeze-thaw study. Moreover, the in vitro release profiles of AST from the optimized SMEDS formulation were significantly improved compared to a marketed preparation and raw AST powder. The design of experiments and optimization of these novel AST SMEDS formulations were a promising approach to enhance dissolution of poorly water-soluble AST.